Trial site
Milan
Milan, 20132, ItalyNot linked to an institution yet
- 14running trials
- 9closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 27 trials
- Phase 1/22 trials
- Phase 11 trial
- Status
- Active, not recruiting9 trials
- Completed9 trials
- Recruiting5 trials
- Lead sponsor
- GlaxoSmithKline18 trials
- ViiV Healthcare4 trials
- Tesaro, Inc.1 trial
Running trials
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609· Phase 1/2· GlaxoSmithKline· Source
Contact: Giuseppe Curigliano (principal investigator)
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898· Phase 3· GlaxoSmithKline· Source
Contact: Antonio Passaro (principal investigator)
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034· Phase 1/2· GlaxoSmithKline· Source
Contact: Filippo Pietrantonio (principal investigator)
Recruiting
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
NCT06567782· Phase 2· GlaxoSmithKline· Source
Contact: Salvatore Siena (principal investigator)
Active, not recruiting
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414· Phase 2· GlaxoSmithKline· Source
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698· Phase 2· GlaxoSmithKline· Source
Contact: Pietro Lampertico (principal investigator)
Active, not recruiting
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Active, not recruiting
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503· Phase 3· ViiV Healthcare· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error